Despite the undisputed effectiveness of agonist maintenance for treating opioid dependence, current capacity is inadequate to meet need in the U.S. and internationally. Indeed, an alarming number of clinics have extensive waitlists for treatment slots. Patients can remain on these waitlists for years, placing them at elevated risk for illicit drug use, criminal activity, infectious disease, overdose and mortality during this perod. These delays in treatment access represent a significant barrier to the widespread delivery of effective opioid treatment, and there is a critical need to develop creative new approaches for mitigating these delays. Our overarching goal in this application is to develop a novel Interim Buprenorphine Treatment (IBT) that can bridge delays in treatment access. Our integrative treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: Buprenorphine, Computerized adherence monitoring, mHealth clinical support delivered via Interactive Voice Response, Automated random call-backs for urinalysis and adherence monitoring, and HIV+Hepatitis Education delivered via iPad. The Primary Aim of this Stage I Behavioral and Integrative Treatment Development application is to evaluate the feasibility and initial efficacy of IBT in a 12-week randomized trial in which 70 opioid-dependent adults wait-listed for agonist maintenance are randomized to receive IBT (n=35) or continue in a Waitlist Control condition (WLC;n=35). WLC participants who have not entered treatment by Week 12 will be offered the opportunity to cross over to IBT at that time, contributing additional within-subject data with which to evaluate the efficacy of the IBT intervention. The proposed research is innovative in several important ways: By facilitating the eradication of waitlists for opioid treatment, it represents a significant departure from the status quo and stands to produce a fundamental shift in how treatment of opioid dependence is conceptualized and delivered. The IBT components are highly novel, both individually and as an integrative interim treatment package for opioid dependence. This study will be the first to investigate the utility of IBT in th patients and settings that stand to benefit most from it. We also propose a multi-pronged dissemination approach that will ensure that our work is readily transported to clinical practice and will have a direct impact on real-world treatment of opioid dependence. Taken together, the proposed project will produce a highly innovative technology-assisted pharmacotherapy protocol that can be widely disseminated to increase access to life-saving opioid treatment. The overarching and specific aims of this proposal are directly relevant to NIDA's mission of improving the accessibility, implementation and effectiveness of drug abuse treatment.
Despite the undisputed effectiveness of agonist maintenance for treating opioid dependence, an alarming number of clinics, both nationally and internationally, have extensive waitlists for treatment slots. We propose to leverage efficacious pharmacotherapy, state-of-the-art technology and rigorous methodology to develop a novel Interim Buprenorphine Treatment that can bridge these delays in treatment access. The proposed project will produce a highly innovative technology-assisted pharmacotherapy protocol that can be widely disseminated to increase access to life-saving opioid treatment.
|Dunn, Kelly E; Barrett, Frederick S; Yepez-Laubach, Claudia et al. (2016) Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting. J Subst Abuse Treat 71:1-7|
|Dunn, Kelly E; Barrett, Frederick S; Yepez-Laubach, Claudia et al. (2016) Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids. J Addict Med 10:314-23|
|Dunn, Kelly E; Barrett, Frederick S; Herrmann, Evan S et al. (2016) Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. Drug Alcohol Depend 168:69-75|
|Sigmon, Stacey C (2016) Additive burdens of malnutrition, poverty, and substance abuse. Lancet 388:1879-1880|
|Dunn, Kelly E; Saulsgiver, Kathryn A; Miller, Mollie E et al. (2015) Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug Alcohol Depend 151:47-55|
|Sigmon, Stacey C; C Meyer, Andrew; Hruska, Bryce et al. (2015) Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. Addict Behav 51:136-42|
|Fenn, Jennifer M; Laurent, Jennifer S; Sigmon, Stacey C (2015) Increases in body mass index following initiation of methadone treatment. J Subst Abuse Treat 51:59-63|
|Meyer, Andrew C; Miller, Mollie E; Sigmon, Stacey C (2015) Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers. Addict Behav 42:189-93|
|Sigmon, Stacey C (2015) Interim treatment: Bridging delays to opioid treatment access. Prev Med 80:32-6|
|Sigmon, Stacey C (2015) The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry 72:395-6|
Showing the most recent 10 out of 11 publications